Chemotherapy-related dysphonia: Similar and differentiating features of six cases
| Autor: | Seiichiro Kuroda, Yohei Iimura, Dai Shida, Susumu Aikou, Kentaro Yazawa, Yuka Ahiko, Tomohiro Kurokawa, Giichiro Tsurita, Yoshiaki Kanemoto |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Vascular Endothelial Growth Factor A
Oncology medicine.medical_specialty Bevacizumab Recombinant Fusion Proteins medicine.medical_treatment Peripheral edema Angiogenesis Inhibitors Quality of life Ranibizumab Internal medicine otorhinolaryngologic diseases medicine Humans Panitumumab Pharmacology (medical) Aflibercept Pharmacology Chemotherapy business.industry Cancer Dysphonia medicine.disease Receptors Vascular Endothelial Growth Factor Quality of Life Nivolumab medicine.symptom business medicine.drug |
| Zdroj: | Int. Journal of Clinical Pharmacology and Therapeutics. 59:780-783 |
| ISSN: | 0946-1965 |
| Popis: | Dysphonia has been reported with anti-angiogenic chemotherapy agents. Dysphonia in patients with cancer receiving chemotherapy tends to be overlooked in clinical practice since it is non-life-threatening. However, it reduces quality of life. Although inhibition of vascular endothelial growth factor receptor is the reported mechanism of dysphonia, it has not been elucidated. We report 6 cases of patients with dysphonia suspected to be due to panitumumab and nivolumab that have not been reported previously. Peripheral edema, a factor in dysphonia, can be seen with aflibercept, bevacizumab, panitumumab, and nivolumab. Therefore, chemotherapy drugs with peripheral edema may be related to dysphonia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|